Shopping Cart 0
Cart Subtotal
USD 0

ANI Pharmaceuticals Inc (ANIP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

ANI Pharmaceuticals Inc (ANI) formerly BioSante Pharmaceuticals Inc, is a specialty pharmaceutical company that develops, manufactures and markets pharmaceuticals. The company's product portfolio encompasses generic and branded tablets indicated for ulcerative colitis; osteoarthritis; rheumatoid arthritis; primary hypercholesterolemia; severe hypertriglyceridemia; arrhythmia; obsessive-compulsive disorder; social anxiety disorder; ulcerative proctitis; ulcerative proctosigmoiditis; bipolar disorder; glaucoma; metastatic prostate cancer; diarrhea; and pain. It caters to markets including oncolytics; complex formulations, hormones and steroids; and controlled substances. ANI also undertakes contract manufacturing of coated and non-coated capsules; oral dosage forms; liquid solution; topical liquids; suspension forms; and tablets. The company sells its products to wholesalers, group purchasing organizations, mail order houses in the US, and pharmacy retail outlets. ANI is headquartered in Baudette, Minnesota, the US.

ANI Pharmaceuticals Inc (ANIP)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13

Asset Purchase 13

ANI Pharma to Acquire Generic Products from Amneal Pharma and Impax Labs 13

ANI Pharma to Acquire Manufacturing Equipment from Amneal Pharma and Impax Labs 15

ANI Pharma Acquires Generic ANDA Product Portfolio from IDT Australia for USD2.7 Million 16

ANI Pharma Acquires Four NDA's from AstraZeneca 17

ANI Pharma Acquires Inderal XL from Cranford Pharma for USD20 Million 18

ANI Pharma Acquires InnoPran XL from Holmdel Pharma for USD31 Million 19

ANI Pharma Acquires Inderal LA Assets from Cranford Pharma 20

ANI Pharma Acquires Two NDAs from Merck Sharp & Dohme for USD75 Million 21

ANI Pharma Acquires Rights to Testosterone Gel 1% from Teva Pharma 22

ANI Pharma Acquires ANDA from Teva Pharma 23

ANI Pharma Acquires Vancocin Capsules and Vancomycin Assets from Shire for USD11 Million 24

ANI Pharma Acquires Lithobid from Noven Therapeutics for USD12 Million 25

ANI Pharma Acquires 22 Generic Drug Products from Teva Pharma 26

Partnerships 27

ANI Pharma Enters into Distribution Agreement with Aspen 27

ANI Pharma Enters into Agreement with H2-Pharma 28

ANI Pharma Enters into Agreement with IDT Australia 29

ANI Pharma Extends Co-Development Agreement With Sterling Pharma 30

ANI Pharma Enters Into Development Agreement With Sterling Pharma 31

Ani Pharma Enters Into Co-Development Agreement With Sofgen Pharma For Oral Soft Gel Prescription Product 32

Merger 33

BioSante Pharma And Ani Pharma Complete Merger 33

Licensing Agreements 35

ANI Pharma Enters into Licensing Agreement with Dexcel Pharma 35

Ani Pharma Enters Into Licensing Agreement With Sofgen Pharma For Oral Soft Gel Product 36

Equity Offering 37

WellSpring Pharma Services Invests USD3 Million in IDT Australia 37

ANI Pharma Completes Public Offering Of Shares For USD 50 Million 38

Debt Offering 39

ANI Pharma Raises USD143.8 Million in Public Offering of 3% Notes Due 2019 39

ANI Pharma Raises USD287.5 Million in Public Offering of 2.125% Notes Due 2023 41

Acquisition 42

ANI Pharma Acquires WellSpring Pharma from Sentinel Capital for USD18 Million 42

ANI Pharmaceuticals Inc-Key Competitors 43

ANI Pharmaceuticals Inc-Key Employees 44

ANI Pharmaceuticals Inc-Locations And Subsidiaries 45

Head Office 45

Other Locations & Subsidiaries 45

Recent Developments 46

Financial Announcements 46

Aug 07, 2018: ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2018 Results and Updates Guidance 46

May 08, 2018: ANI Pharmaceuticals Reports First Quarter 2018 Results and Reaffirms Guidance 51

Feb 27, 2018: ANI Pharmaceuticals Reports Record Full Year Results, Reports Fourth Quarter 2017 Results, and Provides 2018 Guidance 54

Nov 02, 2017: ANI Pharmaceuticals Reports Record Third Quarter and Year-To-Date 2017 Results and Narrows Full Year Guidance 58

Aug 03, 2017: ANI Pharmaceuticals Reports Record Second Quarter and Year-To-Date 2017 Results and Reaffirms Guidance 61

May 04, 2017: ANI Pharmaceuticals Reports First Quarter Results and Year-To-Date 2017 Highlights and Reaffirms Guidance 63

Mar 02, 2017: ANI Pharmaceuticals Reports Full Year 2016 Results and Fourth Quarter Results and Provides 2017 Guidance 65

Corporate Communications 68

Jun 05, 2018: ANI Pharmaceuticals Appoints Three New Board of Directors 68

Appendix 69

Methodology 69

About GlobalData 69

Contact Us 69

Disclaimer 69


List Of Figure

List of Figures

ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

ANI Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

ANI Pharma to Acquire Generic Products from Amneal Pharma and Impax Labs 13

ANI Pharma to Acquire Manufacturing Equipment from Amneal Pharma and Impax Labs 15

ANI Pharma Acquires Generic ANDA Product Portfolio from IDT Australia for USD2.7 Million 16

ANI Pharma Acquires Four NDA's from AstraZeneca 17

ANI Pharma Acquires Inderal XL from Cranford Pharma for USD20 Million 18

ANI Pharma Acquires InnoPran XL from Holmdel Pharma for USD31 Million 19

ANI Pharma Acquires Inderal LA Assets from Cranford Pharma 20

ANI Pharma Acquires Two NDAs from Merck Sharp & Dohme for USD75 Million 21

ANI Pharma Acquires Rights to Testosterone Gel 1% from Teva Pharma 22

ANI Pharma Acquires ANDA from Teva Pharma 23

ANI Pharma Acquires Vancocin Capsules and Vancomycin Assets from Shire for USD11 Million 24

ANI Pharma Acquires Lithobid from Noven Therapeutics for USD12 Million 25

ANI Pharma Acquires 22 Generic Drug Products from Teva Pharma 26

ANI Pharma Enters into Distribution Agreement with Aspen 27

ANI Pharma Enters into Agreement with H2-Pharma 28

ANI Pharma Enters into Agreement with IDT Australia 29

ANI Pharma Extends Co-Development Agreement With Sterling Pharma 30

ANI Pharma Enters Into Development Agreement With Sterling Pharma 31

Ani Pharma Enters Into Co-Development Agreement With Sofgen Pharma For Oral Soft Gel Prescription Product 32

BioSante Pharma And Ani Pharma Complete Merger 33

ANI Pharma Enters into Licensing Agreement with Dexcel Pharma 35

Ani Pharma Enters Into Licensing Agreement With Sofgen Pharma For Oral Soft Gel Product 36

WellSpring Pharma Services Invests USD3 Million in IDT Australia 37

ANI Pharma Completes Public Offering Of Shares For USD 50 Million 38

ANI Pharma Raises USD143.8 Million in Public Offering of 3% Notes Due 2019 39

ANI Pharma Raises USD287.5 Million in Public Offering of 2.125% Notes Due 2023 41

ANI Pharma Acquires WellSpring Pharma from Sentinel Capital for USD18 Million 42

ANI Pharmaceuticals Inc, Key Competitors 43

ANI Pharmaceuticals Inc, Key Employees 44

ANI Pharmaceuticals Inc, Other Locations 45

ANI Pharmaceuticals Inc, Subsidiaries 45

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

ANI Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

ANI Pharmaceuticals Inc (ANI) formerly BioSante Pharmaceuticals Inc, is a specialty pharmaceutical company that develops, manufactures and markets pharmaceuticals. The company's product portfolio encompasses generic and branded tablets indicated for ulcerative colitis; osteoarthritis; rheumatoid arthritis; primary hypercholesterolemia; severe hypertriglyceridemia; arrhythmia; obsessive-compulsive disorder; social anxiety disorder; ulcerative proctitis; ulcerative proctosigmoiditis; bipolar disorder; glaucoma; metastatic prostate cancer; diarrhea; and pain. It caters to markets including oncolytics; complex formulations, hormones and steroids; and controlled substances. ANI also undertakes contract manufacturing of coated and non-coated capsules; oral dosage forms; liquid solution; topical liquids; suspension forms; and tablets. The company sells its products to wholesalers, group purchasing organizations, mail order houses in the US, and pharmacy retail outlets. ANI is headquartered in Baudette, Minnesota, the US.

ANI Pharmaceuticals Inc (ANIP)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13

Asset Purchase 13

ANI Pharma to Acquire Generic Products from Amneal Pharma and Impax Labs 13

ANI Pharma to Acquire Manufacturing Equipment from Amneal Pharma and Impax Labs 15

ANI Pharma Acquires Generic ANDA Product Portfolio from IDT Australia for USD2.7 Million 16

ANI Pharma Acquires Four NDA's from AstraZeneca 17

ANI Pharma Acquires Inderal XL from Cranford Pharma for USD20 Million 18

ANI Pharma Acquires InnoPran XL from Holmdel Pharma for USD31 Million 19

ANI Pharma Acquires Inderal LA Assets from Cranford Pharma 20

ANI Pharma Acquires Two NDAs from Merck Sharp & Dohme for USD75 Million 21

ANI Pharma Acquires Rights to Testosterone Gel 1% from Teva Pharma 22

ANI Pharma Acquires ANDA from Teva Pharma 23

ANI Pharma Acquires Vancocin Capsules and Vancomycin Assets from Shire for USD11 Million 24

ANI Pharma Acquires Lithobid from Noven Therapeutics for USD12 Million 25

ANI Pharma Acquires 22 Generic Drug Products from Teva Pharma 26

Partnerships 27

ANI Pharma Enters into Distribution Agreement with Aspen 27

ANI Pharma Enters into Agreement with H2-Pharma 28

ANI Pharma Enters into Agreement with IDT Australia 29

ANI Pharma Extends Co-Development Agreement With Sterling Pharma 30

ANI Pharma Enters Into Development Agreement With Sterling Pharma 31

Ani Pharma Enters Into Co-Development Agreement With Sofgen Pharma For Oral Soft Gel Prescription Product 32

Merger 33

BioSante Pharma And Ani Pharma Complete Merger 33

Licensing Agreements 35

ANI Pharma Enters into Licensing Agreement with Dexcel Pharma 35

Ani Pharma Enters Into Licensing Agreement With Sofgen Pharma For Oral Soft Gel Product 36

Equity Offering 37

WellSpring Pharma Services Invests USD3 Million in IDT Australia 37

ANI Pharma Completes Public Offering Of Shares For USD 50 Million 38

Debt Offering 39

ANI Pharma Raises USD143.8 Million in Public Offering of 3% Notes Due 2019 39

ANI Pharma Raises USD287.5 Million in Public Offering of 2.125% Notes Due 2023 41

Acquisition 42

ANI Pharma Acquires WellSpring Pharma from Sentinel Capital for USD18 Million 42

ANI Pharmaceuticals Inc-Key Competitors 43

ANI Pharmaceuticals Inc-Key Employees 44

ANI Pharmaceuticals Inc-Locations And Subsidiaries 45

Head Office 45

Other Locations & Subsidiaries 45

Recent Developments 46

Financial Announcements 46

Aug 07, 2018: ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2018 Results and Updates Guidance 46

May 08, 2018: ANI Pharmaceuticals Reports First Quarter 2018 Results and Reaffirms Guidance 51

Feb 27, 2018: ANI Pharmaceuticals Reports Record Full Year Results, Reports Fourth Quarter 2017 Results, and Provides 2018 Guidance 54

Nov 02, 2017: ANI Pharmaceuticals Reports Record Third Quarter and Year-To-Date 2017 Results and Narrows Full Year Guidance 58

Aug 03, 2017: ANI Pharmaceuticals Reports Record Second Quarter and Year-To-Date 2017 Results and Reaffirms Guidance 61

May 04, 2017: ANI Pharmaceuticals Reports First Quarter Results and Year-To-Date 2017 Highlights and Reaffirms Guidance 63

Mar 02, 2017: ANI Pharmaceuticals Reports Full Year 2016 Results and Fourth Quarter Results and Provides 2017 Guidance 65

Corporate Communications 68

Jun 05, 2018: ANI Pharmaceuticals Appoints Three New Board of Directors 68

Appendix 69

Methodology 69

About GlobalData 69

Contact Us 69

Disclaimer 69


List Of Figure

List of Figures

ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

ANI Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

ANI Pharma to Acquire Generic Products from Amneal Pharma and Impax Labs 13

ANI Pharma to Acquire Manufacturing Equipment from Amneal Pharma and Impax Labs 15

ANI Pharma Acquires Generic ANDA Product Portfolio from IDT Australia for USD2.7 Million 16

ANI Pharma Acquires Four NDA's from AstraZeneca 17

ANI Pharma Acquires Inderal XL from Cranford Pharma for USD20 Million 18

ANI Pharma Acquires InnoPran XL from Holmdel Pharma for USD31 Million 19

ANI Pharma Acquires Inderal LA Assets from Cranford Pharma 20

ANI Pharma Acquires Two NDAs from Merck Sharp & Dohme for USD75 Million 21

ANI Pharma Acquires Rights to Testosterone Gel 1% from Teva Pharma 22

ANI Pharma Acquires ANDA from Teva Pharma 23

ANI Pharma Acquires Vancocin Capsules and Vancomycin Assets from Shire for USD11 Million 24

ANI Pharma Acquires Lithobid from Noven Therapeutics for USD12 Million 25

ANI Pharma Acquires 22 Generic Drug Products from Teva Pharma 26

ANI Pharma Enters into Distribution Agreement with Aspen 27

ANI Pharma Enters into Agreement with H2-Pharma 28

ANI Pharma Enters into Agreement with IDT Australia 29

ANI Pharma Extends Co-Development Agreement With Sterling Pharma 30

ANI Pharma Enters Into Development Agreement With Sterling Pharma 31

Ani Pharma Enters Into Co-Development Agreement With Sofgen Pharma For Oral Soft Gel Prescription Product 32

BioSante Pharma And Ani Pharma Complete Merger 33

ANI Pharma Enters into Licensing Agreement with Dexcel Pharma 35

Ani Pharma Enters Into Licensing Agreement With Sofgen Pharma For Oral Soft Gel Product 36

WellSpring Pharma Services Invests USD3 Million in IDT Australia 37

ANI Pharma Completes Public Offering Of Shares For USD 50 Million 38

ANI Pharma Raises USD143.8 Million in Public Offering of 3% Notes Due 2019 39

ANI Pharma Raises USD287.5 Million in Public Offering of 2.125% Notes Due 2023 41

ANI Pharma Acquires WellSpring Pharma from Sentinel Capital for USD18 Million 42

ANI Pharmaceuticals Inc, Key Competitors 43

ANI Pharmaceuticals Inc, Key Employees 44

ANI Pharmaceuticals Inc, Other Locations 45

ANI Pharmaceuticals Inc, Subsidiaries 45

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

ANI Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.